newsfilter
← Latest News
GlobeNewswire·

Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress

– Initial safety and PK/PD data from Phase 1/2 study of exoSTING™ now expected in the fourth quarter of 2021 – – Initial safety and efficacy data from Phase 1 trial of exoIL-12™ in CTCL anticipated by year-end – ��